...
search icon
traw-img

Traws Pharma Inc, Common Stock

TRAW

NAQ

$1.25

-$0.09

(-6.72%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$6.51M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
229.23K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.59
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.97 L
$17.75 H
$1.25

About Traws Pharma Inc, Common Stock

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameTRAWSectorS&P500
1-Week Return2.46%1.9%1.37%
1-Month Return-28.98%1.36%15.76%
3-Month Return-73.35%-8.73%-2.58%
6-Month Return-72.16%-5.96%0.72%
1-Year Return-92.18%-7.97%12.24%
3-Year Return-95.41%3.54%52.73%
5-Year Return-99.11%34.17%100.37%
10-Year Return-100%78.8%180.28%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue231.00K226.00K226.00K226.00K226.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.84,"profit":true},{"date":"2022-12-31","value":97.84,"profit":true},{"date":"2023-12-31","value":97.84,"profit":true},{"date":"2024-12-31","value":97.84,"profit":true}]
Cost of Revenue-14.00K14.00K16.00K12.00K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":87.5,"profit":true},{"date":"2022-12-31","value":87.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":75,"profit":true}]
Gross Profit231.00K212.00K212.00K210.00K214.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":91.77,"profit":true},{"date":"2022-12-31","value":91.77,"profit":true},{"date":"2023-12-31","value":90.91,"profit":true},{"date":"2024-12-31","value":92.64,"profit":true}]
Gross Margin100.00%93.81%93.81%92.92%94.69%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":93.81,"profit":true},{"date":"2022-12-31","value":93.81,"profit":true},{"date":"2023-12-31","value":92.92,"profit":true},{"date":"2024-12-31","value":94.69,"profit":true}]
Operating Expenses25.22M16.72M19.85M20.51M142.60M[{"date":"2020-12-31","value":17.69,"profit":true},{"date":"2021-12-31","value":11.73,"profit":true},{"date":"2022-12-31","value":13.92,"profit":true},{"date":"2023-12-31","value":14.38,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(24.99M)(16.50M)(19.63M)(20.30M)(142.37M)[{"date":"2020-12-31","value":-2499300000,"profit":false},{"date":"2021-12-31","value":-1649600000,"profit":false},{"date":"2022-12-31","value":-1962700000,"profit":false},{"date":"2023-12-31","value":-2029800000,"profit":false},{"date":"2024-12-31","value":-14237400000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(25.15M)(16.16M)(18.96M)(18.95M)(166.52M)[{"date":"2020-12-31","value":-2515300000,"profit":false},{"date":"2021-12-31","value":-1616300000,"profit":false},{"date":"2022-12-31","value":-1896400000,"profit":false},{"date":"2023-12-31","value":-1894800000,"profit":false},{"date":"2024-12-31","value":-16652300000,"profit":false}]
Income Taxes4.00K(321.00K)(214.49K)(151.90K)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-8025,"profit":false},{"date":"2022-12-31","value":-5362.13,"profit":false},{"date":"2023-12-31","value":-3797.38,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(25.16M)(16.16M)(18.96M)(18.95M)(166.52M)[{"date":"2020-12-31","value":-2515700000,"profit":false},{"date":"2021-12-31","value":-1616300000,"profit":false},{"date":"2022-12-31","value":-1896400000,"profit":false},{"date":"2023-12-31","value":-1894800000,"profit":false},{"date":"2024-12-31","value":-16652300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(25.16M)(16.16M)(18.96M)(18.95M)(166.52M)[{"date":"2020-12-31","value":-2515700000,"profit":false},{"date":"2021-12-31","value":-1616300000,"profit":false},{"date":"2022-12-31","value":-1896400000,"profit":false},{"date":"2023-12-31","value":-1894800000,"profit":false},{"date":"2024-12-31","value":-16652300000,"profit":false}]
EPS (Diluted)(54.17)(24.67)(22.67)(0.90)-[{"date":"2020-12-31","value":-5417,"profit":false},{"date":"2021-12-31","value":-2467.3,"profit":false},{"date":"2022-12-31","value":-2266.96,"profit":false},{"date":"2023-12-31","value":-90,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TRAW
Current Ratio 1.81

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TRAW
ROA (LTM) -65.35%
ROE (LTM) -2255.45%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TRAW
Debt Ratio Lower is generally better. Negative is bad. 0.69
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.31

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TRAW
Trailing PE NM
Forward PE NM
P/S (TTM) 31.63
P/B 1.67
Price/FCF NM
EV/R 1.25
EV/Ebitda 0.33

FAQs

What is Traws Pharma Inc share price today?

Traws Pharma Inc (TRAW) share price today is $1.25

Can Indians buy Traws Pharma Inc shares?

Yes, Indians can buy shares of Traws Pharma Inc (TRAW) on Vested. To buy Traws Pharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TRAW stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Traws Pharma Inc be purchased?

Yes, you can purchase fractional shares of Traws Pharma Inc (TRAW) via the Vested app. You can start investing in Traws Pharma Inc (TRAW) with a minimum investment of $1.

How to invest in Traws Pharma Inc shares from India?

You can invest in shares of Traws Pharma Inc (TRAW) via Vested in three simple steps:

  • Click on Sign Up or Invest in TRAW stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Traws Pharma Inc shares
What is Traws Pharma Inc 52-week high and low stock price?

The 52-week high price of Traws Pharma Inc (TRAW) is $17.75. The 52-week low price of Traws Pharma Inc (TRAW) is $0.97.

What is Traws Pharma Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Traws Pharma Inc (TRAW) is 1.67

What is the Market Cap of Traws Pharma Inc?

The market capitalization of Traws Pharma Inc (TRAW) is $6.51M

What is Traws Pharma Inc’s stock symbol?

The stock symbol (or ticker) of Traws Pharma Inc is TRAW

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top